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Double-strand DNA breaks – the breakup that 
hurts both ways
Double-strand DnA breaks (DSB) in DnA occur when the 
phosphodiester backbone of both the strands of the same 
DnA helix is broken, the breakpoints being in proximity of 
each other so that the broken ends may become physically 
separated. this may happen for a variety of reasons – 
physiological and pathological alike – and indeed occurs, 
albeit not very frequently, throughout the life of the cell. DSB 
are considered be a particularly genotoxic type of damage, as 
they not only cause serious alteration of the DnA structure, 
but also generate free (unprotected) DnA ends. the latter are 
reactive and would readily interact with other DnA ends or 
intact DnA, resulting in genomic fusions, deletions, insertions, 
duplications, allelic conversion, loss of heterozygocity, in other 
words, overall genomic instability which in the short term may 
lead to the breakdown of eukaryotic chromosomes into smaller 
fragments, and in the long term may result in inherited disease 
or disease of somatic origin, such as cancer (7, 72, 87). As a 
rule, eukaryotic genomes are not tolerant to the presence of 
DSB, and a burden of several double-strand breaks per genome 
is known to cause rerouting of the cell programme of a non-
cancerous cell to the apoptotic pathway. 
the problem of safekeeping and managing free reactive 
DnA ends in eukaryotic cells has brought the development 
of a number of mechanisms in order to ensure that free ends 
are protected and therefore non-reactive (as is the case with 
the physical ends of the chromosomes which are protected 
by the telomere complex); or that the double-strand breaks 
are promptly repaired (for which several mechanisms exist); 
or that when the cell really requires the presence of DSB at 
some point in its life cycle, the control over the cell programme 
and the management of the generated free ends would be very 
rigorous. the general rule is that unprotected DnA ends are 
sought for and processed where possible, or in most cases the 
cell is sacrificed. This ‘ultimate control’ policy, however, has 
some inherent issues, which may produce different outcomes. 
Shaking it and actually breaking it – events that 
lead to double-strand breaks 
DSB may occur in the genome for a variety of reasons, 
endogenous and exogenous in their origin, and physiological 
and pathological in their nature. certain clastogenic agents, 
such as ionizing radiation (short-wavelength UV included) 
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ABSTRACT
The problem of managing free reactive DNA ends in eukaryotic cells has resulted in the development of a number of mechanisms 
in order to ensure that free ends are rendered non-reactive, or that the double-strand DNA breaks generating the free ends are 
promptly repaired; or that if the cell requires the introduction of double-strand breaks in its DNA at some point in its life cycle, the 
generated free DNA ends would be subject to strictest management. Different mechanisms for dealing with double-strand breaks 
in DNA exist, contributing to the maintenance of the exquisite balance between entering an evolutionary dead end resulting from 
extremely faithful DNA repair and genome instability resulting from relaxed control of repair. Recombination-based mechanisms 
related to the mechanism for repair of double-strand breaks and template slippage during replication are believed to be able to 
account for multiplication of parts of the genome, generating regions of homology which may serve as sites for mispairing during 
meiotic and mitotic recombination, and resulting, in turn, in translocations, deletions and inversions. This is especially true for 
the X chromosome, which engages in homologous recombination with the partnering X chromosome in female meiosis, but will 
participate in only limited partial genomic exchange with the Y chromosome in male meiosis, providing ample opportunities for 
mispairing and non-allelic recombination.  Several X-linked monogeneous diseases and even some chromosome diseases such 
as variants of Turner syndrome have been found to be related to non-allelic homologous recombination during male meiosis, 
resulting in various rearrangements of the X chromosome. Apparently, the mechanisms which protect the mammalian genomes 
from stagnation or, alternatively, from hypermutability, may not always perform adequately. The genome rearrangement disorders 
may be unfortunate manifestations of the ongoing process of reorganization of genetic architecture in the eukaryotic genomes, 
which is inherent to evolution. 
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and radiomimetic chemicals increase the rate of occurrence of 
double-strand breaks in DnA (70). the presence of Z-DnA has 
been shown to increase the risk for occurrence of double-strand 
breaks (42). Meiotic and mitotic recombination, apparently 
the only mechanisms for generation of genetic variability that 
Nature deemed necessary to specifically designate, operate 
by creating and subsequently repairing double-stranded 
breaks. Shortening of telomeres of somatic cells as they move 
towards ageing creates potential targets for the cellular repair 
machinery. Finally, some types of cells explicitly require 
generation of DSB at some point of their life cycle. in any 
case, double-strand breaks in DnA are usually meticulously 
tracked and dealt with, as the potential for generating lasting 
damage is estimated to be much larger for DSB than for any 
other type of damage.
Unprotected chromosome ends
the telomeric complex at the ends of eukaryotic chromosomes 
serves multiple purposes, besides the obvious role in keeping 
the changes in the genome content to the bare minimum. 
Among these purposes specifically prominent is keeping the 
reactive DnA ends away from other DnA and preventing the 
cellular machinery for repair of DSB from being activated 
by the presence of natural chromosome ends. the length of 
the telomeres in the chromosomes of normal somatic cells is 
usually a good indicator of how close the cell is to replicative 
senescence (30), that is, through how many more telomere 
shortenings the cell can safely go without risking triggering 
of genome instability and, ultimately, cancerous growth. it has 
been shown, however, that instead of launching the process of 
ageing at the first appearance of shortened telomeres in a cell, 
these tend to accumulate in the cell for a while before the onset 
of actual senescence (39, 46), making the feat of assessing the 
median length of telomeres in a cell population and correlating 
it to any indices pertaining to the status of the cell population, 
the tissue or the organism very difficult indeed (5, 60, 75). 
Recently, it has been determined that at least five dysfunctional 
telomeres are required in a human cell in order to trigger p53-
dependent senescence (40). Apparently, the risk for genomic 
instability due to telomere attrition is actually tolerated by 
the genome to a certain point before launching any of the 
mechanisms eliminating the cell containing chromosomes 
with shortened telomeres from the population. 
Events in the cellular life cycle which generate free DNA 
ends
Double-strand breaks in DnA may occur as a result of 
biological processes in the cell – not necessarily pathological 
ones. the prime example for this is the differentiation of 
t-cells and B-cells of the immune system, which need to 
introduce multiple DSB in their DnA in order to carry out the 
requisite genomic rearrangements for V(D)J recombination. 
Failure to do so usually results in severe immunodeficiency 
states. the process of genomic rearrangements in immune 
cells is, however, under strict control. Basically, any cell that 
has not received a designated survival signal would proceed to 
apoptosis by default (57, 80). This is rather severe selection, 
and indeed only about 2% of all immature double-positive 
thymocytes survive the rearrangement of their t-cell receptors.
Some types of differentiated cells which are exposed to high 
levels of oxidative damage (and, therefore, tend to experience 
significant amount of double-strand breaks as a consequence 
of the impact of the generated reactive oxygen species), such 
as neurons, tend to carry out preferential repair of transcribed 
genes at the expense of the global genome repair (19, 68). this 
presumably serves a dual purpose. on the one hand, since those 
cells do not generally divide, they are unlikely to replicate their 
damaged DnA, and are therefore in no need to repair genome 
regions that are not currently under transcription. on the other 
hand, this may also ensure that all DSB in critically important 
regions of the genome (currently transcribed genes) are repaired 
in a timely fashion, so that the need to eliminate cells with 
damaged DnA from a cell population that is supposed to last 
for a long time and is not likely to be replenished would arise 
infrequently. indeed, the current theories of brain ageing place 
a strong emphasis on the link between accumulation of DnA 
damage and neurodegeneration. An example for that is ataxia-
telangiectasia (A-t), a genetic disease related to a defect in the 
DSB-activated protein AtM (Ataxia telangiestesia Mutated), 
which is a serine/threonine protein kinase that is recruited and 
activated by DnA double-strand breaks (43). in A-t patients, 
the cells of the thymus (where t-cells mature and carry out 
their genomic rearrangements) and brain cells (exposed to 
oxidative stress) would promptly die by apoptosis triggered 
by physiological events instead of repairing the DnA damage, 
causing the characteristic phenotype of immune deficiency and 
neurological lesions (100). 
Meiotic recombination and sister chromatid exchange
Recombination during meiosis produces genetic diversity 
in the resulting gametes, thus creating unique allelic 
combinations to be tested and, if found favourable, 
propagated further. Recombination in prophase i of meiosis 
is fully legitimate between regions which are both allelic and 
homologous between the DnA sequences participating in 
the recombination. non-allelic homologous recombination 
(nAhR), that is, recombination between regions sharing 
homology but belonging to different loci) occurs relatively 
frequently too, though the effects are generally mitigated by 
the bulk of noncoding DnA in the genome. it is currently 
believed that non-allelic homologous recombination and other 
recombination events related to replication (such as break-
induced replication, see below) are responsible for a significant 
proportion of inherited genomic disease and cancer (23, 44). 
exchange of genetic material also occurs between sister 
chromatids during mitosis, though this is usually ‘silent’ in 
genetic aspect, as sister chromatids are (presumably) identical 
and the event is relatively infrequent, amounting to several 
exchange events per chromosome pair per cell cycle (95). 
excessive sister chromatid exchange, caused by molecular 
defects in certain DnA repair proteins produces chromosomal 
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instability and a disease phenotype, namely, Bloom syndrome 
(91). homologous recombination is believed to be the main 
mechanism in sister chromatid exchange, providing precise 
repair of double-strand breaks in actively proliferating cells 
and suppressing tumorigenesis (63).
Break up to make up – strategies cells use to 
process double-strand breaks in DNA
Apart from the specific mechanisms managing natural 
chromosome ends, several mechanisms for dealing with DSB 
exist. each of these has its advantages as well as its limitations, 
contributing to the exquisite balance between genomic 
stagnation resulting from extremely faithful DnA repair and 
hypermutability resulting from relaxed control of repair. 
Non-homologous end joining (NHEJ)
Basically, broken ends may be rejoined by ligation after 
making sure that a free 3’–OH and a 5’–phosphate are present, 
for which some nucleotides at the damage site may be excised 
and subsequently resynthesized. this does not require the 
presence of a homologous template, and is therefore known 
as non-homologous end joining (nheJ). nheJ is critically 
important in V(D)J recombination in immune cells, allowing 
the B- and t-cells to deploy their huge antigen-recognizing 
potential by introducing complex genomic rearrangements 
into the genes coding for the t-cell receptor and the antibody 
loci, respectively. An important part of the process is adding 
of non-template nucleotides, increasing the diversity of the 
resulting molecules (24). Defects in genes coding for products 
participating in the nheJ pathway (DnA ligase iV and nheJ1) 
in humans usually produces a phenotype of severe immune 
deficiency with radiosensitivity (12, 69). NHEJ is a generally 
error-prone repair pathway. on the other hand, it is associated 
with loss or rewriting of the genetic information from the site 
surrounding the DSB (52). To this adds the error rate of the 
polymerases participating in the resynthesis of DnA, which 
generally lack proofreading properties. however, since the 
eukaryotic genomes contain a significant amount of noncoding 
DnA, nheJ is a viable option for repairing double-strand 
breaks, as it is highly efficient. Its error-proneness introduces a 
certain amount of genetic variability, too, though it can cause 
incorrect joining of ends producing potentially deleterious 
genomic rearrangements (3).
Homologous recombination (HR)
When there are areas of homology between the sequences 
containing broken DnA ends, more than one mechanism may 
be engaged to ensure that repair is carried out without loss 
of genetic information or that the sequence of the region in 
the vicinity of the DSB is recovered with minimal losses or 
alterations. homologous recombination may be subdivided 
into several sub-pathways – generally, double-strand break 
repair (DSBR), synthesis-dependent strand annealing (SDSA), 
and break-induced replication (BiR or break-copy replication) 
(55). Generally, all three mechanisms require the presence 
of a homologous template DnA molecule and a single-
stranded 3’–OH end to initiate the invasion and pair to the 
homologous template. DSBR may generate non-crossover 
or crossover products between the template DnA molecule 
and the molecule undergoing repair. SDSA generally results 
in non-crossover products, leaving the template strand in its 
initial state. BiR is carried out when the double-strand breaks 
occur in DnA molecules currently undergoing replication. it 
generates entirely non-reciprocal crossovers, as a replication 
fork at the site of the free-end invasion may proceed with 
subsequent DnA synthesis up the end of the replicated region 
– presumably, to the end of the chromosome (33, 58). All three 
mechanisms may result in gene conversion, i.e. substituting 
one part of the DnA sequence for another. When there is 
multiple allelism in the loci undergoing repair, this may result 
in loss of heterozygocity. in SDSA, however, the region of the 
conversion is limited on both ends of the initial double-strand 
break, while both DSBR and BiR could presumably cause 
substitution of all DnA sequence after the break site. 
When occurring at sites of microhomology (homologous 
sequences only several bp long), the mechanism of BiR 
may alter the genome in a quantitative as well as in a 
qualitative manner (microhomology-mediated BiR, MMBiR), 
introducing at breakpoint junctions DnA sequences derived 
from elsewhere in the genome (31, 104). on one hand, this 
would increase the number of copies in which a sequence 
is presented in the genome. on the other, it would produce 
discontinuity in genomic sequences, deleting certain regions, 
multiplicating others and translocating certain parts of the 
genome to other locations, placing them in the ‘correct’ or 
the ‘reverse’ orientation to the direction of transcription of the 
recipient locus. 
Fork stalling and template switching (FoSteS) is a 
mechanism closely related to MMBiR. Basically, it proposes 
that during DnA replication the replication fork can stall 
and switch templates using complementary template 
microhomology to anneal and prime DnA replication (47, 
107). the involved forks can be close to each other or may be 
separated by considerable distances. the mechanism enables 
the joining of different sequences located in different positions 
in the genome and can result in complex non-reciprocal 
rearrangements, recurring as well as non-recurring ones. 
Single-strand annealing 
there is yet another mechanism for repair of DSB which 
require a homologous DnA sequence as a template, but not 
necessarily on a separate DnA molecule. this mechanism is 
known as the single-strand annealing (SSA) pathway for repair 
of double-strand breaks (34, 89). SSA uses repeated sequences 
within the same DnA molecule as sources of partial homology. 
SSA is error-prone, as is NHEJ, and bears significant mutagenic 
potential, not only because the DnA polymerase that performs 
the resynthesis of DnA is not very accurate, but also because 
of the fact that the DnA sequence between the repeats is 
invariably lost, as is one of the two participating repeats.
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Breaking may be a new beginning – but of what, 
exactly?
Apparently, leaving double-strand breaks unrepaired is not an 
option, as this would result in undesired genetic instability. 
Adequateness of recombinational repair is, however, a different 
matter. homologous recombination is the staple mechanism 
for generating potential for adaptation. it works to resolve 
double-strand breaks in a relatively precise manner, utilising 
the capacity of DnA to preserve its sequence information in 
duplicate. the greatest strength of homologous recombination 
is, however, the source of its greatest weakness, as sequences 
with only partial homology may serve as templates for 
homologous recombination. Such sequences are quite 
common in mammalian genomes. it has been proposed that 
the mechanisms of gene duplication coupled with subsequent 
divergence and exon shuffling, in other words the basic drives 
of molecular evolution of genomes, are results of the FoSteS/
MMBIR mechanisms (107), and, that they operated on a ‘trial 
and error’ principle like all evolutionary mechanisms. As a 
result of multiplication and translocation of sequences, regions 
of more or less partial homology are densely interspersed within 
all mammalian chromosomes, within the same chromosome 
as well as between different chromosomes. For example, А 
domains of human Factor VІІІ (located on the X-chromosome, 
Xq28) are highly homologous to the A domains of Factor V 
(chromosome 1q) and ceruloplasmin (chromosome 3q) (38). 
Similarly, the c domains of Factor Viii are homologous 
to the c domains of Factor V; the human clotting proteins 
iX (Xq27), Vii (chromosome 13q34), X (also 13q34), 
and protein c (chromosome 2q) all possess an n-terminal 
gamma-carboxyglutamic acid-containing domain followed 
by two EGF-like domains, etc. (97). In the human genome, 
copy number is considered a significant part of the overall 
genome variation, with the regions with variable copy number 
estimated to be up to 12% of the overall genome content (78). 
Apparently, variation in copy number is tolerated to an extent 
and may even have some hitherto unknown advantage to the 
carrier, but disorders related to abnormal gene dosage due to 
multiplication and rearrangement of genomic fragments are 
quite common. 
non-allelic homologous recombination (nAhR) occurs 
between DnA sequences which exist in more than one copy and 
exhibit high sequence homology, but are not polymorphic forms 
of the same allele. especially noteworthy are the so-called low-
copy repeats (lcR), which are spaced relatively far apart from 
each other (in the order of several hundreds of kilobases), in either 
orientation to one another (36, 96). Recombination between 
regions of homology may cause rearrangement of sizeable 
genome fragments – deletions of the intervening sequence, 
when the recombination occurs between straight repeats and 
inversions, when the breakpoint junctions are within inverted 
repeats. Unreciprocal exchanges of genome fragments between 
sequences sharing partial homology may result in duplication. 
low-copy repeats may be of variable length, from several kb 
up to several hundred kb and usually share over 95% identity. 
homologous recombination is stimulated by several orders of 
magnitude after introduction of a DSB in a repeated sequence 
(63). Presumably, this ensures that the break is repaired in the 
safest possible way, using closely related sequences. When 
the genome contains more than one closely related sequence, 
however, errors are unavoidable. 
Better leave it broken than get hurt trying to 
repair it – how repair machinery may actually 
go wrong when doing everything right
Balanced genomic rearrangements, even large ones, may be 
asymptomatic to their carriers and may only be discovered 
when the consequences of an unbalanced rearrangement 
manifest in the progeny. Many genes actually can perform 
very well with a single genomic copy only, too, provided 
that this copy is not subject to epigenetic activation (e.g. 
genomic imprinting) – though somatic inactivation of the 
surviving copy may trigger neoplastic growth. Autosomal 
genes generally can rely on homologous repair of DSB using 
the copy on the other chromosome as a template, though the 
resultant gene conversion may have undesired effects. the 
situation is radically different for the X chromosome, which 
can pair up and engage in homologous recombination in 
prophase i with the partnering X chromosome in females, but 
would have to negotiate a complicated genomic exchange with 
the Y chromosome in males. 
The X chromosome is quite large, approximately 155 Mb 
in length (81) and containing between 1000 and 2000 genes 
and about 1000 pseudo genes. less than 30 genes on the X 
chromosome are shared with the Y chromosome (59). During 
meiosis, the X and the Y chromosomes only pair within their 
pseudoautosomal regions (PAR), located in the terminal 
regions of the arms of these chromosomes. PARs are relatively 
short and may be not even be present, as deletion of parts or the 
whole of these regions is not very rare, the genomic fragments 
containing the missing genes sometimes being added to the X 
and Y chromosomes (29, 59). Interspersed repeats account for 
more than half of the X-chromosomal euchromatin, with line1 
repeat elements covering about 30% of all X chromosome 
sequence. intrachromosomal segmental duplications account 
for about 2.5% of the X chromosome, which is over than 10 
times more than the rate of segmental duplication seen in any 
of the autosome pairs. 
Apparently, recombination has been (and currently is) at 
work at the X chromosome, occasionally producing disease 
phenotypes. Since a significant number of genes are specific 
to the X-chromosome only, it is not surprising that these 
phenotypes become manifest principally in males, with females 
being asymptomatic carriers. What is highly significant, 
however, is the fact that they actually occur predominantly 
during male meiosis, presumably in an X chromosome that 
cannot pair full-length with the Y and therefore becomes 
prone to non-allelic homologous recombination involving its 
various repeated elements. Several allegedly monogeneous 
diseases and even chromosome diseases such as some variants 
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of turner syndrome have been found to be, in fact, genome 
rearrangement disorders, related to genomic reorganization 
on the X chromosome. these rearrangements affect not only 
the gene which produces the general phenotype but also the 
adjoining genomic sequences, the latter being of considerable 
length in some cases. Replication-based mechanisms such 
as break-induced replication are likely to account for most 
genomic rearrangements of the duplication/multiplication 
type (22). Subsequent non-allelic homologous recombination 
between the generated regions of homology results, in turn, 
in translocations, deletions and inversions, the direct result 
being a high male/female ratio of germline mutations in the 
X chromosome (96, 102). the idea that diseases traditionally 
associated in the public mind with female transmission actually 
may result from a mutation originating in males apparently 
still presents quite a challenge for genetic counseling for 
X-linked disease of the affected families (6, 32, 73, 77). the 
specificities of the genomic rearrangements resulting in some 
of these common conditions are presented below. 
Rearrangements in the Factor VIII and Factor IX genes 
hemophilia A is a severe disorder of blood clotting, resulting 
from mutations in the Factor Viii gene (Xq28). the latter 
contains 16 exons and spans 186 kb, taking about 0.1% of 
the length of the X-chromosome. the mutation spectrum of 
haemophilia A is fairly heterogeneous, except from a gross 
molecular rearrangement which affects 40-50% of the severe 
cases and approximately 20-25% of all cases of haemophilia A. 
this molecular defect is essentially an inversion-translocation 
of the genome region containing exons 1-22 and the adjoining 
noncoding sequence, which places the inverted region at a 
300-400 kb distance from the distal part of the gene (45, 66). 
the rearrangement has been traced to recombination between 
repeated regions approximately 10 kb in length sharing a very 
high degree of homology (over 99.9%) which are represented 
in one intragenic and two or (rarely) more extragenic copies 
located on the same chromosome at a distance of about 300 
and 400 kb, respectively, from the Factor VIII locus  (51). 
the relatively large scale of the mutation caused considerable 
difficulties to genetic analysis (35, 53, 74), which actually 
resulted in obtaining very detailed data on the nature of the 
mutation and the underlying mechanism. the prevalence of the 
inversion is very similar in all studied populations, as it results 
from a random event (non-allelic homologous recombination 
within the X-chromosome is believed to be a stochastic event). 
there is slight difference between the prevalence of rare 
inversion types (which involve the intragenic and the third, the 
fourth, etc. extragenic copy) in different populations, which is 
related to how common the individuals carrying more than two 
extragenic copies in the studied population are. Virtually all 
mothers of boys with inversion-type haemophilia A are found 
to be carriers for the inversion, which led to the conclusion that 
the causative mutation originated predominantly in male germ 
cells (83), therefore causing healthy males to have carrier 
daughters which, in turn, give birth to affected boys. With 
support from linkage analysis of the X chromosome, it was 
proposed that mispairing resulting in incorrect recombination 
occurs during male meiosis, when the single X chromosome 
is only partially paired with the Y, creating ample opportunity 
for close contact of homologous regions elsewhere on the 
chromosome (10, 83). The phenomenon of ‘mutation type-
dependent sex ratio of mutation frequencies’, as the authors 
called it, does not extend only to gross gene rearrangements. 
Another relatively common (5% of severe cases) defect 
causing haemophilia A, inversion of intron 1, has been proven 
to originate exclusively in the male germline too (1). Partial or 
complete factor VIII gene deletions are found in about 5% of 
the families with severe hemophilia A, some of which include 
recombinations of repeated sequences of the line1 and Alu 
type (82, 103). Family analysis shows that, similarly to the 
inversion with breakpoints in the 10 kb repeat in intron 22, the 
index patient carrying the rearrangement in Factor Viii gene 
is usually the first case in the family, born to a carrier mother 
(50), and that most (though not all) rearrangements occur in 
the male germline (10, 64). 
homologous recombination between repeats producing 
deletions or inversions in the Factor iX gene (a close neighbour 
to Factor Viii on the long arm of the X chromosome) have 
been found to be the most common causative mutation in 
haemophilia B as well, and the male/female ratio of occurrence 
of mutations has been found to be close to 4 (41). in 2007, 
studying a patient with a contiguous gene syndrome including 
haemophilia A, two adjacent deletion/insertion events were 
found that were reportedly explained best by break-induced 
replication mechanism (93).
Rearrangements in the dystrophin gene
Duchenne/Becker muscular dystrophy is another common 
X-linked disease in which the affected males are often the 
first and only case in the family, born to asymptomatic carrier 
females and exhibiting distinctive male-to-female germline 
ratio of occurrence of some type of mutations (26). the gene 
is located on Xp21 and is one of the largest genes in the human 
genome, containing 79 exons and spanning about 2 300 kb of 
genomic DNA (1.5% of all the X-chromosome) (101). Genomic 
rearrangements, mainly deletions, but also duplications and 
inversions with flanking deleted sequences are responsible for 
over 60% of the cases of DMD/BMD (71). it has been found 
that the sites of rearrangements often contained short regions 
of homology with other sites on the X chromosome, which 
presumably self-paired during male meiosis (28, 62, 94). in 
2009, a recombination-related mechanism related to presence 
of repeated elements was proposed to explain the apparent 
genomic instability of the regions between exons 8 and 13 
and between exons 45 and 52 which constituted the two major 
mutational hotspots in the dystrophin gene (71). Recently, in a 
larger study, comprised of DMD cases as well as other X-linked 
disorders, it was found that regions of microhomology (2-10 
bp) were observed at breakpoint junctions in about 60% of the 
study cases which, according to the authors, were remnants of 
template slippage during break-induced replication (4). 
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Turner syndrome with other than 45(XO) karyotype
turner syndrome results from complete or partial monosomy 
for the X chromosome. The typical 45, XO karyotype is seen 
in about half of the patients. the most frequent (almost 20%) 
variant karyotype, however, presents with an isodicentric 
X chromosome with two q-arms, so that the cell is partially 
monosomic for the p arms (37). it has been found that the 
breakpoint regions in many isodicentric X chromosomes 
included large inverted repeats composed of clusters of 
repeated sequences, and that most isodicentric X chromosomes 
result from non-allelic homologous recombination between 
palindromic sequences (44, 92). the role of regions of 
microhomology and FoSteS in generation of dicentric X 
chromosomes has also been discussed (44). 
Other rearrangements with clinical significance in the X 
chromosome
Pelizaeus-Merzbacher disease (PMD) is an X-linked 
demyelinating disorder caused by mutation in the gene 
encoding proteolipid protein-1 (PLP1) in humans (Xq22). the 
major cause for PMD are duplications (about 60% of all PLP1 
mutations), which occur predominantly in the male germline 
(61) and with breakpoints in low-copy repeats (48, 49, 79, 107). 
Similar is the situation with the MECP2 gene (Xq28), 
coding for a chromatin-associated protein which binds 
methylated CpGs, activating or repressing transcription of 
target sequences. Defects in the MECP2 gene may produce 
the phenotype of Rett disorder in humans (2). Duplications 
including the MECP2 gene are commonly seen in genomic 
rearrangements identified in neurodevelopmentally delayed 
males (14). these rearrangements are supposedly generated 
by the FoSteS mechanism (9, 14). Both in PlP1 (Xq22) and 
in MecP2 (Xq28) loci a complicated rearrangement has been 
found, namely, a duplication-inverted triplication-duplication 
mediated by inverted repeats (13). 
Mucopolysaccharidosis ii is often a product of massive 
(20-30 kb) inversions or deletions of the iDS locus on 
Xq, involving the functional gene copy and the respective 
pseudogene (27). this is believed to be a nAhR-mediated 
event, occurring predominantly during male meiosis (27, 90). 
Fixing it the wrong way – aberrant repair of 
free DNA ends and double-strand breaks in 
cancer cells 
Apparently, the diversity of mechanisms nature has provided to 
make sure that all free DnA ends are joined to one another or 
protected may not always work in the right direction. this does 
not extend to meiosis only, but may involve somatic cells as 
well, especially cancer cells. For example, alternative telomere 
lengthening (Atl) is a mechanism for telomere elongation other 
than the conventional teRt-catalyzed synthesis of telomeric 
repeats using the RnA template provided by teRc. Alternative 
elongation of telomeric DnA is carried out using as a template 
telomeric DNA from other telomeres (15, 34). Utilization of 
Atl has been demonstrated so far in cancer cells only, but 
makes up for an impressive 10-15% of all cancers (25). 
cancer cells may or may not express high levels of teRt, 
but they often possess fusion-prone free chromosome ends 
resulting from replication stress. these reactive free ends may 
become joined by the nheJ mechanism, forming a dicentric 
chromosome which will promptly break at the next anaphase 
in cellular division, when the two centromeres are pulled apart, 
producing more free ends, thereby closing the vicious cycle 
(56, 65). 
the prevalence of null genotypes for glutathione 
S-transferases such as GSTT1 and GSTM1 is quite common 
in caucasian and Asian populations, amounting to an average 
frequency above 50% (11). The GSTM1 and GSTM2 genes 
are likely to have been produced by gene duplication, as they 
have very high level of sequence identity, with the GSTM1 
null allele probably resulting from non-allelic homologous 
recombination (106). carriership of null alleles of these genes 
is associated with increased level of DnA damage and elevated 
baseline level of sister chromatid exchanges increasing the 
probability of somatic recombination, which has been linked 
to an increase of the risk of various cancers (67, 105).
Recently, it has been proposed that in some types of tumours, 
especially bone cancer (76, 98), the genomic instability occurs 
not in the random fashion, which could be expected according 
to the gradual damage accumulation model of carcinogenesis, 
but in a single catastrophic event, termed ‘chromothripsis’, 
affecting localized regions on one or several chromosomes. 
Briefly, according to the authors, the affected region is literally 
shattered into fragments, some (but not all) of which are 
subsequently brought together again by the cellular machinery 
for DNA. Since it is not possible to determine the ‘right’ order 
of the genomic fragments, these are urgently patched together 
using the error-prone mechanism of nheJ into a more or less 
random order, with all possible consequences of such a ‘cut-
and-paste’ activity (22). Under such circumstances, it is likely 
that at least one, and, possibly, more molecular events typical 
of cancerous transformation would occur, therefore, cells 
who have undergone chromotripsis are much more likely to 
have acquired exceptional proliferation capacity and to have 
become capable of ignoring the apoptotic signals as a result. 
Re(tying) the knot – how the deleterious results 
of double-strand breaks could be repaired by 
introducing yet more double-strand breaks
Modern research and medicine already possess various tools 
to assess capacity for DnA repair and, sometimes, to intervene 
where this is possible (8, 16, 17, 18, 20, 54, 86, 99). In vitro 
assays for the rate of repair of double-strand breaks have been 
developed in order to be used in testing for cancer susceptibility 
and radiosensitivity (8, 85, 88). Recently, it has been proposed 
that molecular events causing disruptions of the reading 
frame of a gene could be corrected by introducing double-
strand breaks in the desired DnA sequences using designated 
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nucleases, then employing the error-prone mechanism of 
nheJ to join the free ends. Mutations disrupting the reading 
frame of a gene, even by deleting or inserting only a single 
nucleotide, often have more deleterious effects than mutations 
eliminating whole exons of the same gene, provided that in 
the second case the remaining parts of the sequence splice in-
frame. thus, by using nheJ on pre-cut sequences containing 
mutations disrupting the reading frame, it could be expected 
that micro-insertions or micro-deletions would be generated 
at the joining site, which may effectively restore the reading 
frame though at the expense of several improperly added 
nucleotides or, alternatively, risking a loss of one or more 
amino acid residues. As of now this has been demonstrated 
in vitro with out-of-frame mutated dystrophin gene (21, 84). 
It is also believed that specific nuclease activities coupled 
with subsequent nheJ could be used for targeting sequences 
containing a nonsense mutation and deleting them, or 
introducing more than one DSB in sites flanking an inserted or 
translocated sequence, causing its excision (21, 49). 
Conclusions
the role of DnA repair mechanisms in maintaining the balance 
between genome stability and genome variability has been 
intensively studied for the last decades. it has only recently 
been proposed that the mechanisms which protect the genomes 
from stagnation or, alternatively, from hypermutability, may 
not always perform adequately and that some allegedly 
monogeneous diseases are, in fact, manifestations of the 
ongoing process of rearrangement of genetic architecture in the 
eukaryotic genomes, which is inherent to evolution. continued 
research in the field of genome dynamics and rearrangement-
based disorders is likely to bring new opportunities for 
combating human disease, inherited as well as conditions 
related to somatic mutagenesis. 
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